IPHA
Innate Pharma S.A.
NASDAQ · Healthcare · Biotechnology · FR
$2.08
−1.42%Margins
Gross margin
100.0%
EBITDA margin
-666.4%
EBIT margin
-681.5%
Net margin
-638.9%
FCF margin
-421.0%
453.8%
Return on equity
-157.0%
Return on assets
—
Return on invested capital
0.20x
Asset turnover
-$74.8M
Cash from operations
$0.36
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Dec 1, 2025